Zynex Relocates Englewood, Colorado, Headquarters
10/30/2017
The company's proprietary NeuroMove device is designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.
According to company officials, the new building is less than one mile from the existing headquarters and will expand the footprint from approximately 17,000 square feet to approximately 43,800 square feet, with a first right of refusal to occupy additional space in the building. The lease is for sixty-six months and can be extended by another two years until June 30, 2025.
Thomas Sandgaard, CEO said, "Our recent growth has made it necessary for us to lease larger office and manufacturing space to accommodate not only a higher level of activity as well as anticipated future growth.”
“We continue to outsource many functions, such as electronic assembly, in an effort to have as much flexibility in our growth as possible. We expect to move into the new space in January 2017," he added.
Project Announcements
Kimberly-Clark Expands Aiken County, South Carolina, Distribution Operations
05/04/2025
Aerowerks Plans Gaffney, South Carolina, Manufacturing Operations
05/04/2025
Sweden-Based Troax Group Plans Portland, Tennessee, Manufacturing Operations
05/04/2025
Kimberly-Clark Corporation Plans Warren, Ohio, Manufacturing Operations
05/04/2025
Denmark-Based Novonesis Expands Salem, Virginia, Production Operations
05/04/2025
Polyvlies USA Expands Winston-Salem, North Carolina, Manufacturing Operations
05/04/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024